利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

40 条记录 (耗时 0.031 秒)

    Synthetic antigens of luteinizing hormone releasing hormone
    1.
    发明授权
    Synthetic antigens of luteinizing hormone releasing hormone 失效
    黄体激素释放激素的合成抗原

    公开(公告)号：US3963691A

    公开(公告)日：1976-06-15

    申请号：US512563

    申请日：1974-10-07

    申请人： Carl H. Hoffman ,  Harvey Schwam ,  Stephen F. Brady ,  Martin Hichens ,  Ruth F. Nutt

    发明人： Carl H. Hoffman ,  Harvey Schwam ,  Stephen F. Brady ,  Martin Hichens ,  Ruth F. Nutt

    IPC分类号： A61K39/00 ,  C07K5/097 ,  C07K5/103 ,  C07K7/23 ,  C07C103/52 ,  C07G7/00

    CPC分类号： C07K5/0821 ,  C07K5/1005 ,  C07K7/23 ,  A61K39/00 ,  Y10S514/80 ,  Y10S530/812 ,  Y10S530/815 ,  Y10S930/13 ,  Y10S930/28

    摘要： Synthetic antigens related to luteinizing hormone-releasing hormone (hereinafter designated LH-RH) having the amino acid composition, pyroglutamyl-histidyl-tryptophanylseryl-tyrosyl-glycyl-leucyl-arginyl-prolyl-glycyl-poly-L-lysine (hereinafter designated pyroglu-his-trp-ser-tyr-glyleu-arg-pro-gly-poly-L-lys) and poly-L-lysyl-glutarylhistidyl-tryptophanyl-seryl-tyrosyl-glycyl-leucyl-arginylprolyl-glycine amide (hereinafter designated poly-L-lysglutaryl-his-trp-ser-tyr-gly-leu-arg-pro-gly) are prepared by coupling the corresponding decapeptide with poly-L-lysine. The corresponding decapeptides are prepared by controlled stepwise procedures starting with individual amino acid components. These antigens have the property of inducing formation of antibodies to luteinizing hormone-releasing hormone (LH-RH) in animals.

    摘要翻译： 与具有氨基酸组成的促黄体激素释放激素（以下称为LH-RH）相关的合成抗原，焦谷氨酰 - 组氨酰基 - 色氨酰基 - 酰基 - 酪氨酰 - 甘氨酰 - 亮氨酰 - 精氨酰 - 脯氨酰 - 甘氨酰 - 聚-L-赖氨酸（以下称为pyroglu- his-trp-ser-tyr-glyleu-arg-pro-gly-poly-L-lys）和聚-L-赖氨酰 - 戊二酰基组氨酰基 - 色氨酸 - 丝氨酰 - 酪氨酰 - 甘氨酰 - 亮氨酰 - 炔丙基 - 甘氨酰胺（下文称为聚 - 通过将相应的十肽与聚-L-赖氨酸偶联来制备L-赖氨酰赖氨基-he-trp-ser-tyr-gly-leu-arg-pro-gly）。 相应的十肽通过从各个氨基酸组分开始的受控逐步方法制备。 这些抗原具有在动物体内诱导形成促黄体激素释放激素（LH-RH）的抗体的性质。

    Peptides having ANF activity
    2.
    发明授权
    Peptides having ANF activity 失效
    具有ANF活性的肽

    公开(公告)号：US5091366A

    公开(公告)日：1992-02-25

    申请号：US534001

    申请日：1990-06-04

    申请人： Ruth F. Nutt ,  Terrence M. Ciccarone ,  Stephen F. Brady ,  Daniel F. Veber

    发明人： Ruth F. Nutt ,  Terrence M. Ciccarone ,  Stephen F. Brady ,  Daniel F. Veber

    IPC分类号： A61K38/00 ,  C07K14/58

    CPC分类号： C07K14/58 ,  A61K38/00

    摘要： Analogs of the 17-membered ring portion of ANF wherein the cysteine moiety is replaced with dipeptidyl moieties, specifically, Phe-Pro, NMP-Pro, Pro-Pro, Val-Pro, Lys-Pro, Ile-Pro, Arg-Pro, HAr-Pro, Dly-Pro, Arg-Pro, Lys-BAr, Arg-Pro, CyA-CyA, Cys-Cys, or with .alpha.-aminoheptanoic acid result in analogs of ANF having increased potencies and metabolic stability.

    摘要翻译： ANF的17-元环部分的类似物，其中半胱氨酸部分被二肽基部分，特别是Phe-Pro，NMP-Pro，Pro-Pro，Val-Pro，Lys-Pro，Ile-Pro，Arg-Pro， HAr-Pro，Dly-Pro，Arg-Pro，Lys-BAr，Arg-Pro，CyA-CyA，Cys-Cys或α-氨基庚酸导致ANF的类似物具有增加的效力和代谢稳定性。

    Piptides having ANF activity
    3.
    发明授权
    Piptides having ANF activity 失效
    具有ANF活性的鱼类

    公开(公告)号：US4816443A

    公开(公告)日：1989-03-28

    申请号：US51980

    申请日：1987-05-19

    申请人： Stephen F. Brady ,  Ruth F. Nutt

    发明人： Stephen F. Brady ,  Ruth F. Nutt

    IPC分类号： A61K38/00 ,  A61P7/10 ,  A61P9/00 ,  A61P9/12 ,  C07K7/08 ,  C07K14/00 ,  C07K14/575 ,  C07K14/58 ,  A61K37/02 ,  C07K7/10

    CPC分类号： C07K14/58 ,  A61K38/00

    摘要： Novel peptides having potent natriuretic activity are disclosed with the following amino acid sequence: ##STR1## wherein Z is H, acetyl, Boc or Ser-Leu, E is Phe, NMP, OMT, ChA, F is Gly or DAl, G is Ala or Gly, H is Arg or DAr, Pro, Lys or Dly, I is Ile, Met, MeO, MO.sub.2, Leu, Nle, or Val, J is Aib, .alpha.MG or .alpha.MA, K is Arg or Lys, L is Ile or Val, M is Aib, Gly, Ala or DAl, N is Ala, NMA, Pro, Phe or NMP, O is Gln, DGl, Ala or DAl, P is Ser, His, Arg or Lys, Q is Gly, Pro, Ala or Dal, R is Leu, Phe or ChA, S is Gly, Ala or Dal, Arg or DAr, T is Asn DAs, Ala or Dal, U is Ser, DSe, Ala or DAl, V is Phe, DPh, Ala or DAl, Y is -OH or -NH.sub.2 and n is 0 or 1. Also included are the lower alkyl esters and the physiologically acceptable metal salts and acid addition salts of the foregoing peptides. Unless indicated otherwise all optically active amino acids have the L-configuration.